MoSaiC2: Circulating Fetal Cells and Breast Cancer
Study Details
Study Description
Brief Summary
After pregnancy, fetal cells remain in a woman's body for years. These cells may be involved in different physiological situations (e.g. wound healing) and diseases (e.g. cancer).The study will evaluate the level of circulating fetal immune cells in patients with breast cancer vs controls with benign breast tumors, and further characterize these fetal cells. Patients participation will be limited to accepting that an additional blood sample is collected on the day of their preop consultation and blood test.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
Breast cancer is the most common cancer in the female population. The protective mechanism associated with pregnancy is not fully understood.
During pregnancy fetal cells cross the placental barrier and may remain in the maternal circulation even for up to 30 years after childbirth. This phenomenon is called fetal microchimerism.
The presence of circulating fetal cells would have a protective role against breast cancer. However, their phenotype and role in the anti-tumor response is not explored.
The objective of the study is to identify the sub-population (s) of circulating fetal immune cells that may have an impact on the processes of carcinogenesis in breast cancer, in the context of fetal microchimerism.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Patients women 18-50 years with previous history of a male birth scheduled for malignant breast tumor surgery |
Other: Blood sample
As part of the treatment, 2 EDTA tubes of 10mL will be taken during a scheduled venipuncture as part of the preoperative assessment.
|
| Controls women 18-50 years with previous history of a male birth scheduled for benign breast tumor surgery or cancer free |
Other: Blood sample
As part of the treatment, 2 EDTA tubes of 10mL will be taken during a scheduled venipuncture as part of the preoperative assessment.
|
Outcome Measures
Primary Outcome Measures
- Percentages of fetal cells in each immune cell subpopulation. [3 years]
Using fluorescence activated cell sorting method.
Secondary Outcome Measures
- Activation markers. [3 years]
Using immunocytochemistry method.
- Cytotoxicity markers. [3 years]
Using immunocytochemistry method.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
women aged 18-50
-
having had a male child
-
informed and not having objected to participating in the research.
Patients:
- having a diagnosis of breast cancer
Controls:
-
operated on for benign breast tumors
-
cancer free
Exclusion Criteria:
-
autoimmune disease
-
immunomodulatory treatment
-
history of cancer other than breast cancer
-
ongoing hormonal treatment
-
women not affiliated to the social security
-
under AME (state medical aid)
-
under tutorship / curatorship
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Hôpital de Tenon-Service de Gynécologie Obstétrique et Médecine de la Reproduction | Paris | France | 75020 |
Sponsors and Collaborators
- Assistance Publique - Hôpitaux de Paris
- Ruban Rose
Investigators
- Principal Investigator: Nathalie CHABBERT-BUFFET, PUPH, Assistance Publique - Hôpitaux de Paris
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- APHP190505
- 2019-A00703-54